论文部分内容阅读
目的:探究阿昔洛韦与伐昔洛韦在预防频发性生殖器疱疹复发的临床效果。方法:选取频发性生殖器疱疹患者91例,随机分为观察组和对照组;其中观察组患者服用伐昔洛韦进行治疗,对照组患者服用阿昔洛韦进行治疗;观察两组患者一年内复发次数、复发率以及脱落细胞排毒状况。结果:观察组患者一年内复发次数(1.2±0.4)次,复发患者4例,复发率8.89%,脱落细胞中检测到病毒的患者10例;对照组患者一年内复发次数(2.3±0.6)次,复发患者12例,复发率26.09%,脱落细胞中检测到病毒的患者20例。结论:伐昔洛韦比阿昔洛韦预防频发性生殖器疱疹复发的效果更显著,可以改善患者症状,降低复发率,适合临床推广使用。
Objective: To investigate the clinical efficacy of acyclovir and valacyclovir in the prevention of recurrent genital herpes. Methods: Ninety patients with frequent genital herpes were randomly divided into observation group and control group. The patients in observation group were treated with valacyclovir and the patients in control group were treated with acyclovir. The patients in two groups were observed within one year The number of relapse, relapse rate and exfoliated cell detoxification status. Results: In the observation group, the number of recurrence in one year was (1.2 ± 0.4) times, in 4 cases of recurrence, the recurrence rate was 8.89%. In the exfoliated cells, 10 cases were detected in the virus. In the control group, the number of recurrence in one year was (2.3 ± 0.6) times , 12 cases of recurrence, the recurrence rate was 26.09%, and 20 cases of virus were detected in exfoliated cells. Conclusion: valaciclovir than acyclovir prevent recurrence of genital herpes more effective, can improve the symptoms of patients and reduce the recurrence rate, suitable for clinical use.